Tag Archive for: relapsed or refractory large B-cell lymphoma

AstraZeneca is strengthening its oncology pipeline with the acquisition of TeneoTwo, which has an ongoing Phase I trial in relapsed and refractory B-cell non-Hodgkin lymphoma, in a deal valued at up to $1.27 billion. 

The U.S. Food and Drug Administration has a handful of PDUFA dates over the next two weeks.